Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedOct 24, 2025
DataAggregated Company Financials
Companies63
  • 7D5.8%
  • 3M13.7%
  • 1Y-0.7%
  • YTD3.5%

In the last week, the Life Sciences industry is up 5.8%, with Thermo Fisher Scientific up 6.5%. The industry has been flat over the past 12 months despite the gain this week. Looking forward, earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 24 Oct 2025US$651.0bUS$145.2bUS$14.6b33.4x44.5x4.5x
Sun, 21 Sep 2025US$573.4bUS$144.3bUS$14.6b30.7x39.4x4x
Tue, 19 Aug 2025US$583.4bUS$144.2bUS$14.5b28.8x40.3x4x
Thu, 17 Jul 2025US$524.4bUS$142.9bUS$9.1b35.6x57.4x3.7x
Sat, 14 Jun 2025US$537.5bUS$142.9bUS$9.2b35.7x58.6x3.8x
Mon, 12 May 2025US$505.4bUS$142.8bUS$9.6b34.4x52.7x3.5x
Wed, 09 Apr 2025US$509.1bUS$142.5bUS$9.9b32x51.2x3.6x
Fri, 07 Mar 2025US$602.1bUS$143.1bUS$9.8b41.9x61.7x4.2x
Sun, 02 Feb 2025US$691.5bUS$143.0bUS$10.4b41.1x66.5x4.8x
Tue, 31 Dec 2024US$657.8bUS$142.4bUS$10.2b44.3x64.3x4.6x
Thu, 28 Nov 2024US$660.7bUS$142.4bUS$10.2b44.4x64.6x4.6x
Sat, 26 Oct 2024US$680.4bUS$142.0bUS$8.3b35.4x82.3x4.8x
Mon, 23 Sep 2024US$746.6bUS$141.8bUS$8.5b37.7x87.9x5.3x
Wed, 21 Aug 2024US$746.1bUS$141.9bUS$8.3b38.2x90x5.3x
Fri, 19 Jul 2024US$697.6bUS$141.2bUS$12.2b39.9x57.1x4.9x
Sun, 16 Jun 2024US$695.0bUS$141.3bUS$12.2b37.1x57.1x4.9x
Tue, 14 May 2024US$724.6bUS$141.5bUS$12.6b38.5x57.7x5.1x
Thu, 11 Apr 2024US$742.9bUS$142.0bUS$12.8b43.4x58.1x5.2x
Sat, 09 Mar 2024US$754.1bUS$142.1bUS$12.8b44.5x58.8x5.3x
Mon, 05 Feb 2024US$709.3bUS$147.5bUS$12.5b38.3x56.6x4.8x
Wed, 03 Jan 2024US$706.4bUS$153.9bUS$14.2b37.7x49.8x4.6x
Fri, 01 Dec 2023US$643.6bUS$153.8bUS$14.0b35x45.9x4.2x
Sun, 29 Oct 2023US$565.9bUS$153.8bUS$11.3b29.2x50.3x3.7x
Tue, 26 Sep 2023US$674.7bUS$154.6bUS$11.2b33.7x60.2x4.4x
Thu, 24 Aug 2023US$713.3bUS$154.6bUS$11.2b32.8x63.6x4.6x
Sat, 22 Jul 2023US$741.4bUS$155.5bUS$12.7b29.4x58.4x4.8x
Mon, 19 Jun 2023US$704.3bUS$152.4bUS$12.5b29.3x56.3x4.6x
Wed, 17 May 2023US$672.0bUS$152.4bUS$12.6b28.2x53.2x4.4x
Fri, 14 Apr 2023US$744.3bUS$154.6bUS$10.8b30.7x68.9x4.8x
Sun, 12 Mar 2023US$693.6bUS$154.5bUS$10.9b29.6x63.9x4.5x
Tue, 07 Feb 2023US$758.4bUS$155.7bUS$9.1b31.5x83.3x4.9x
Thu, 05 Jan 2023US$734.2bUS$155.2bUS$8.8b28.9x83.7x4.7x
Sat, 03 Dec 2022US$781.0bUS$155.1bUS$8.8b28.9x89x5x
Mon, 31 Oct 2022US$720.5bUS$154.5bUS$13.0b27x55.6x4.7x
Price to Earnings Ratio

55.6x


Total Market Cap: US$720.5bTotal Earnings: US$13.0bTotal Revenue: US$154.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 44.5x which is lower than its 3-year average PE of 61.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 4.2% per year over the last three years.
  • Meanwhile revenues for these companies have declined 2.2% per year.
  • This means that less sales are being generated overall, but since cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.29%
Healthcare2.04%
Life Sciences5.83%
Clinical Research and Equipment5.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$571.916.5%
+US$13.3b		2.6%PE32.9x
DHR DanaherUS$222.735.6%
+US$6.5b		-10.2%PE45x
WST West Pharmaceutical ServicesUS$307.2515.0%
+US$2.9b		-7.1%PE45.3x
IQV IQVIA HoldingsUS$219.916.9%
+US$2.4b		3.9%PE30.2x
MEDP Medpace HoldingsUS$596.6114.5%
+US$2.1b		81.8%PE38.7x

Latest News

TMO
US$571.91
Thermo Fisher Scientific
7D
6.5%
1Y
2.6%
MEDP
US$596.61
Medpace Holdings
7D
14.5%
1Y
81.8%
WST
US$307.25
West Pharmaceutical Services
7D
15.0%
1Y
-7.1%
ICLR
US$180.00
ICON
7D
-4.5%
1Y
-18.8%
IQV
US$219.91
IQVIA Holdings
7D
6.9%
1Y
3.9%

Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings

The analyst price target for IQVIA Holdings has increased by approximately $5 to $223, as analysts cite the company's business resilience, workforce stability, and diversified client base as key drivers for higher valuation. Analyst Commentary Recent analyst updates highlight a mix of confidence and caution regarding IQVIA Holdings' future outlook, referencing the company's performance, client diversification, and sector positioning.
PSNL
US$9.45
Personalis
7D
-8.1%
1Y
101.1%
DHR
US$222.73
Danaher
7D
5.6%
1Y
-10.2%

Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.
TEM
US$87.04
Tempus AI
7D
-4.4%
1Y
88.3%
ADPT
US$17.16
Adaptive Biotechnologies
7D
-0.6%
1Y
279.6%

EMR Integration And Partnerships Will Reshape Clinical Diagnostics

Analysts have raised their price target for Adaptive Biotechnologies from $14.86 to $16.00. They cite the company’s strong positioning in cancer testing and sustained revenue growth potential.
A
US$147.46
Agilent Technologies
7D
4.5%
1Y
12.8%

Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress

Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).
MTD
US$1,437.75
Mettler-Toledo International
7D
5.7%
1Y
11.2%

Pharmaceutical And Food Production Expansions Will Unlock Future Opportunities

Analysts have modestly raised their price target for Mettler-Toledo International by approximately $19 to $1,328. They cite incremental improvements in fair value and profit margin projections as the reason for this adjustment.
QSI
US$2.20
Quantum-Si
7D
-13.4%
1Y
183.7%
DNA
US$13.21
Ginkgo Bioworks Holdings
7D
-12.6%
1Y
66.4%

Life Sciences Automation Will Stagnate Amid Regulatory Challenges

Analysts have raised their price target for Ginkgo Bioworks Holdings from $11.33 to $12.00 per share, citing a notable Q2 topline beat and improved cost management as key drivers for the revised outlook. Analyst Commentary Following the recent performance and guidance update, analyst opinions on Ginkgo Bioworks Holdings remain mixed, reflecting both the company’s progress and outstanding challenges.
WAT
US$355.68
Waters
7D
6.2%
1Y
8.7%

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.
MXCT
US$1.62
MaxCyte
7D
-8.5%
1Y
-57.4%
ABCL
US$5.71
AbCellera Biologics
7D
-2.2%
1Y
111.5%